Zacks Investment Research·6d ago
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for NowXRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
DENTSPLY SIRONA is emerging from a period of severe operational and balance-sheet stress, with 2026Q2 showing a rebound to 54.9% gross margin and positive net income of $37M, yet revenue contracted 4.1% year-over-year to $898M, indicating demand remains weak. ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.52+49.4% vs $0.35 | $898M+0.9% vs $890M |
Q2 2026 May 5, 2026 | $0.27-3.6% vs $0.28 | $880M+4.5% vs $842M |
Q1 2026 Feb 26, 2026 | $0.27-3.6% vs $0.28 | $961M+3.8% vs $926M |
Q4 2025 Nov 6, 2025 | $0.37-17.8% vs $0.45 | $904M-2.5% vs $927M |
XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.
Benchmark XRAY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for DENTSPLY SIRONA Inc. (XRAY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.78 | $1.96B | -3.26 | -2.98% | -16.25% | -36.43% | 6.56% | |
| $148.17 | $10.61B | 26.22 | 0.9% | 9.99% | 10.09% | — | |
| $85.05 | $9.69B | 26.01 | 4.03% | 2.96% | 8.38% | — | |
| $23.82 | $3.88B | 85.07 | 8.32% | 3.33% | 4.1% | — | |
| $87.07 | $5.19B | 40.88 | 11.66% | 9.22% | 9.07% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
DENTSPLY SIRONA Inc. (XRAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
DENTSPLY SIRONA Inc. (XRAY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 11, 2026·SEC
Jun 4, 2026·SEC
Get notified when XRAY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DENTSPLY SIRONA Inc. (XRAY) stock FAQ — growth, dividends, profitability & financials explained
DENTSPLY SIRONA Inc. (XRAY) reported $3.64B in revenue for fiscal year 2025. This represents a 455% increase from $656.6M in 1996.
DENTSPLY SIRONA Inc. (XRAY) saw revenue decline by 3.0% over the past year.
DENTSPLY SIRONA Inc. (XRAY) reported a net loss of $546.0M for fiscal year 2025.
Yes, DENTSPLY SIRONA Inc. (XRAY) pays a dividend with a yield of 6.56%. This makes it attractive for income-focused investors.
DENTSPLY SIRONA Inc. (XRAY) has a return on equity (ROE) of -36.4%. Negative ROE indicates the company is unprofitable.
DENTSPLY SIRONA Inc. (XRAY) generated $131.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
